Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
NCT ID: NCT00271323
Last Updated: 2009-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
14 participants
INTERVENTIONAL
2005-05-31
2007-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Secondary : To determine efficacy in term of overall response, disease free survival and survival at 1 and 2 years.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Induction chemotherapy followed by concurrent chemoradiotherapy
docetaxel and cisplatin
Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
2
Concurrent chemo-radiotherapy followed by consolidation chemotherapy
radiotherapy
Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
docetaxel and cisplatin
Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
radiotherapy
Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma or a combination of these)
3. Patients must have a loco regionally advanced unresectable NSCLC;
* Stage IIIA with clinical multiple N2 nodes (preferably with histological or cytological confirmation).
* Patients with peripheral tumours of the lower lobe with contralateral upper mediastinal nodes at station N2 are excluded·
* Stage IIIB T4 or N3.
* In the T4 category, patients with pleural or pericardial effusion and multiple nodules in the same lobe are excluded.
* Patients with T4 disease secondary to extensive and massive involvement of the great vessels are excluded.Patients should be excluded when the expected risk of pulmonary toxicity is likely to be high, e.g. V20 in excess of 35%.
4. Males or females aged between 18 and 75 years.
5. Life expectancy of at least 12 weeks.
6. WHO performance status 0 or 1.
7. Weight loss \<=10% within the last 3 months.
8. Laboratory requirements at entry (within 7 days before randomization):
* Blood cell counts:
* Absolute neutrophils \>= 2.0 x 10\^9/L
* Platelets \>= 100 x 10\^9/L
* Hemoglobin \>= 10 g/dl
* Renal function:
* Serum creatinine \<=1 x the upper limit of normal (UNL). In case of borderline value of serum creatinine, the 24h creatinine clearance should be \>= 60 mL/min.
* Hepatic function:
* Serum bilirubin \<= 1 x UNL
* ASAT and ALAT \<= 2.5 x UNL
* Alkaline phosphatase \<= 5 x UNL Patients with ASAT and/or ALAT \> 1.5 x UNL associated with alkaline phosphatase\> 2.5 x UNL are not eligible for the study.
9. Lung function tests at entry:
* FEV1: \>= 50 % x Normal value
* DLCO: \>= 50 % x Normal value
10. Adequate cardiac function.
11. Patient with either measurable and/or non-measurable lesion (according to RECIST criteria).
Exclusion Criteria
2. Pregnant or lactating women.
3. Patients (male or female) with reproductive potential not implementing adequate contraceptive measures.
4. Prior systemic chemotherapy, immunotherapy, or biological therapy including neoadjuvant or adjuvant treatment for NSCLC.
5. Prior surgery for NSCLC, if less than 5 years from study.
6. Prior radiotherapy for NSCLC.
7. History of prior malignancies, except for cured non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years.
8. Symptomatic peripheral neuropathy Grade \>= 2 except if due to trauma.
9. Other serious concomitant illness or medical conditions:
* Congestive heart failure or angina pectoris except if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.
* History of significant neurological or psychiatric disorders including dementia or seizures.
* Active infection requiring IV antibiotics.
* Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid therapy.
* Superior vena cava syndrome contra-indicating hydration.
* Preexisting pericardial effusion.
* Preexisting symptomatic pleural effusion.
10. Significant gastrointestinal abnormalities, including requirement for intravenous nutrition, active peptic ulcer disease, prior surgical procedures affecting absorption.
11. Distant metastasis.
12. Concurrent treatment with any other experimental anti-cancer drugs.
13. Concomitant or within 4-week period administration of any other experimental drug under investigation.
14. Significant ophthalmologic abnormalities.
15. Moderate to severe dermatitis.
16. Hypersensitivity to docetaxel, cisplatin, or any of its excipients.
17. Concomitant use of phenytoin, carbamazepin, barbiturates, or rifampicin.
18. Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study.
19. Patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to return for follow-up visits, and not likely to complete the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sanofi-aventis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
M COUDERC, Dr
Role: STUDY_DIRECTOR
Sanofi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sanofi-Aventis
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT #: 2005-001276-12
Identifier Type: -
Identifier Source: secondary_id
XRP6976B_2507
Identifier Type: -
Identifier Source: org_study_id